The generic version of Nucynta is expected to be released after 03 July, 2026. This release is predicated by the expiry of the last patent on 27 June, 2025. The earliest generic release could potentially happen via a Para IV filing.
Nucynta is used for the relief of moderate to severe acute pain. The effectiveness of the drug is due to its active ingredient, tapentadol hydrochloride, which has analgesic properties.
Nucynta holds 2 drug patents, of which 1 has expired. The expiration date of the last patent is 27 June, 2025. This is crucial information for the potential release of Nucynta generic. Below are the details of the patents: